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Background: Many patients with asthma remain symptomatic despite treatment with inhaled
corticosteroids (ICS) with or without long-acting b2-agonists (LABAs). Tiotropium add-on to ICS plus a
LABA has been shown to improve lung function and reduce exacerbation risk in patients with symp-
tomatic asthma.
Objective: To determine whether the efﬁcacy of tiotropium add-on therapy is dependent on patients’
baseline characteristics.
Methods: Two randomized, double-blind, parallel-group, twin trials (NCT00772538 and NCT00776984)
of once-daily tiotropium Respimat® 5 mg add-on to ICS plus a LABAwere performed in parallel in patients
with severe symptomatic asthma. Exploratory subgroup analyses of peak forced expiratory volume in 1 s
(FEV1), trough FEV1, time to ﬁrst severe exacerbation, time to ﬁrst episode of asthma worsening, and
seven-question Asthma Control Questionnaire responder rate were performed to determine whether
results were inﬂuenced by baseline characteristics.
Results: 912 patients were randomized: 456 received tiotropium and 456 received placebo. Tiotropium
improved lung function, reduced the risk of asthma exacerbations and asthma worsening, and improved
asthma symptom control, compared with placebo, independent of baseline characteristics including gender,
age, bodymass index, diseaseduration, age at asthmaonset, andFEV1%predicted at screeningand reversibility.
Conclusion: Once-daily tiotropium 5 mg compared with placebo improved lung function, reduced the risk of
asthmaexacerbationsandasthmaworsening, and improvedasthmasymptomcontrol, independentof abroad
range of baseline characteristics, as add-on to ICS plus LABAs in patients with severe symptomatic asthma.
Trial registry: ClinicalTrials.gov; numbers NCT00772538 and NCT00776984 URL: www.clinicaltrials.gov.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).rol Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; CI, conﬁdence interval; FEV1, forced expiratory volume in
haled corticosteroids; IgE, immunoglobulin E; LABA, long-acting b2-agonist; LTRA, leukotriene receptor antagonist; NC,
rced expiratory volume in 1 s within 3 h after the administration of maintenance therapy and study drug; SD, standard
e to Increased Inhaled Glucocorticoid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid.
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Despite treatment according to guidelines with inhaled corti-
costeroids (ICS) as monotherapy or in combination with long-
acting b2-agonists (LABAs) [1], at least 40% of patients diagnosed
with asthma remain symptomatic [2e4].
One option to improve asthma control in patients who remain
symptomatic despite treatment with ICS, with or without a LABA, is
the addition of another controller therapy [1]; the long-acting
anticholinergic bronchodilator tiotropium has recently been
incorporated into the Global Initiative for Asthma 2015 treatment
strategy as an option for addition at steps 4 and 5 in adult patients
with a history of exacerbations [1]. The clinical efﬁcacy and safety of
treatment with tiotropium as add-on to standard ICS maintenance
treatment, with or without a LABA, have been demonstrated in
several trials in adult patients across severities of symptomatic
asthma [5e13].
In studies of patients with mild or moderate disease receiving
maintenance treatment with ICS alone, tiotropium improved lung
function and asthma control [5,7,8,10,11,13], and similar efﬁcacy
was conﬁrmed in three studies comparing the efﬁcacy of tio-
tropium with salmeterol as add-on to ICS [5,7,10]. In patients with
more severe asthma e symptomatic despite treatment with ICS
(800 mg budesonide or equivalent) plus a LABA e a short-term
trial demonstrated signiﬁcant improvements in lung function
following tiotropium add-on therapy [6]. Lastly, in a similar patient
population, two large phase III, 48-week, randomized, double-
blind, placebo-controlled studies with identical design (Primo-
TinA-asthma®) conﬁrmed that tiotropium 5 mg as add-on provides
signiﬁcant and sustained bronchodilation [9]. In these studies,
tiotropium also reduced the risk of severe exacerbations and
asthma worsening by 21% (hazard ratio: 0.79; p ¼ 0.03) and 31%
(hazard ratio: 0.69; p < 0.001), respectively [9]. Signiﬁcant
improvements in lung function and asthma symptom control were
also observed with the 5 mg dose in a phase III, 52-week study in
Japanese patients with symptomatic asthma despite ICS with or
without a LABA [12]. The long-term safety of tiotropiumwas found
to be comparable with that of placebo [9,12].
Tiotropium has been shown to be efﬁcacious across asthma
severities, but it has yet to be determined whether there is a clinical
phenotype or characteristic that predicts whether patients with
asthmawill respond favorably to the addition of this treatment. The
purpose of the current analyses was to explore whether there are
features that may be used to predict which patients might beneﬁt
from the introduction of tiotropium 5 mg compared with placebo in
terms of improvements in lung function and reduction in the risk of
exacerbations or asthmaworsening. We present subgroup analyses
of data from the two phase III PrimoTinA-asthma® studies per-
formed in patients with severe symptomatic asthma despite
treatment with ICS plus LABA therapy [9]. The potential predictive
features examined included, among other characteristics, age,
smoking status, forced expiratory volume in 1 s (FEV1) reversibility,
and allergic status. We also assessed whether the lung function
beneﬁts and reduction in the risk of exacerbations or asthma
worsening translate into improved asthma symptom control and
quality of life in the full patient population.
2. Methods
2.1. Study design
Two phase III, 48-week, randomized, double-blind,
placebo-controlled, parallel-group, twin studies (PrimoTinA-
asthma®: NCT00772538 and NCT00776984) were conducted in
parallel, using the same protocol, at 148 sites in 15 countriesbetween October 2008 and July 2011, to assess the efﬁcacy and
safety of tiotropium 5 mg as add-on to ICS plus LABA maintenance
therapy in symptomatic patients with severe persistent asthma.
The trials were carried out in accordance with the Declaration of
Helsinki and Good Clinical Practice, and all participating patients
provided written, informed consent. Full details of the study design
and main results have been published previously [9].
2.2. Patients
The trials included patients who were aged 18e75 years with a
5-year history of asthma at study enrollment and initial diagnosis
before the age of 40 years, and who were currently symptomatic as
deﬁned by a seven-question Asthma Control Questionnaire (ACQ-7)
mean score of 1.5 [14]. Eligible patients also had moderate or
severe persistent airﬂow limitation, deﬁned as post-bronchodilator
FEV1 80% of predicted normal and 70% of the forced vital
capacity measured 30 min after inhaling four puffs of 100 mg sal-
butamol (albuterol) at their initial screening visit. All patients had
been receiving daily treatment with both ICS (800 mg budesonide
or equivalent dose of another ICS) and a LABA for at least 4 weeks
before screening. Patients must also have experienced at least one
exacerbation requiring treatment with systemic glucocorticoids in
the previous year and either never to have smoked or to have
smoked for less than 10 pack-years with no smoking in the year
before enrollment.
The main exclusion criteria were chronic obstructive pulmonary
disease, serious unstable co-existing illnesses, and an asthma
exacerbation or respiratory tract infection within 4 weeks before
enrollment. Full details of inclusion and exclusion criteria have
been published previously [9].
2.3. Study treatments
Following a 4-week screening period, patients were randomized
in a 1:1 ratio to once-daily tiotropium 5 mg (two puffs of 2.5 mg) or
matching placebo in the morning, both via the Respimat® Soft
Mist™ inhaler (Boehringer Ingelheim, Ingelheim am Rhein, Ger-
many), as add-on therapy to their existing ICS (800 mg budesonide
or equivalent dose) plus LABA treatment regimen, which continued
unaltered.
The use of other maintenance therapies during the study, such
as theophylline, leukotriene receptor antagonists (LTRAs),
anti-immunoglobulin E (IgE) antibody, or oral glucocorticoids
(5mg/day), was allowed provided the dose had been stable for4
weeks before study entry and remained unaltered. In addition,
systemic steroids were permitted for the treatment of severe
asthma exacerbations [9]. Open-label, metered-dose inhalers of
salbutamol were provided as rescue medication.
2.4. Assessments
Patients attended study clinics for assessment on 10 occasions
during the trials: an initial screening visit (Visit 1, Week 4); at
randomization to study treatment (Visit 2, baseline, Week 0); at
Weeks 4 and 8; and then every 8 weeks until Week 48 (Visit 9, end
of treatment). A follow-up visit atWeek 52 was scheduled to record
adverse events and concomitant therapies. During these visits,
patients underwent lung function tests, completed the ACQ-7 and
Asthma Quality of Life Questionnaire (AQLQ), and were questioned
about exacerbations and adverse events.
2.5. Study endpoints
For each trial, the co-primary endpoints included peak FEV1
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therapy and study drug (peak FEV1(0e3h)) and trough FEV1
response, measured at the end of the dosing interval (24 h after
drug administration), 10min before the next dose, atWeek 24 [9]. A
third pre-speciﬁed co-primary endpoint, evaluated from the 48-
week pooled data, was time to the ﬁrst severe asthma exacerba-
tion, deﬁned as a deterioration of asthma necessitating initiation, or
at least a doubling, of systemic glucocorticoids for 3 days [9,15].
Secondary endpoints (pooled data) included time to the ﬁrst
episode of asthma worsening, deﬁned as at least one asthma
symptom outside the patient’s usual range that lasted for 2
consecutive days and/or a decrease in the patient’s best morning
peak expiratory ﬂow 30% from their mean morning peak expi-
ratory ﬂow for 2 consecutive days [9].
Analyses of both pre-planned and post hoc subgroups of pooled
study data were performed to determine whether lung function
results at Week 24, time to ﬁrst severe exacerbation and ﬁrst
episode of asthmaworsening over 48 weeks, and asthma control at
Weeks 24 and 48 with tiotropium 5 mg add-on therapy varied ac-
cording to patients’ baseline characteristics. The pre-planned sub-
groups included: gender; body mass index; FEV1 % predicted at
screening; FEV1 reversibility (following 400 mg salbutamol);
allergic status by clinician judgment, serum IgE, or blood eosino-
phils; B16 combination genotype in the coding region of the b2-
adrenergic receptor gene (only in patients who consented to
participate in the pharmacogenetics portion of the trials); and
country/region. In addition, post hoc subgroups were deﬁned for
the assessment of the efﬁcacy of treatment according to patients’
age, disease duration, age at asthma onset, smoking status, LTRA
use at baseline, race, and ethnicity. The subgroups were chosen on
the basis that patients with or without these disease or de-
mographic characteristics might exhibit differing levels of response
to tiotropium 5 mg add-on therapy. The thresholds used to deﬁne
the subgroups and corresponding rationales are presented in
Table S1.
Overall pooled analyses of ACQ-7 responder rates at Weeks 24
and 48 are also presented to allow for comparisonwith other phase
III trials in which ACQ-7 responder rate was an endpoint. Lastly,
pooled analyses of AQLQ responder rate at Weeks 24 and 48 were
performed. A response was deﬁned as a change in ACQ-7 or AQLQ
score from study baseline of 0.5, the minimal clinically important
difference [16,17].
2.6. Statistical analyses
Univariate subgroup analyses were performed using subgroup-
restricted regression analyses (i.e. analyses within subgroups):
mixed-model repeated measures for peak FEV1(0e3h) and trough
FEV1; Cox regression for time to ﬁrst severe exacerbation and time
to ﬁrst episode of asthma worsening; and logistic regression for
ACQ-7 responder rate. Additional testing for interactions was per-
formed by introducing “subgroup” and “subgroup-by-treatment-
interaction” terms into the analysis models. Subgroup analyses
were largely pre-speciﬁed in the protocol (see 2.5 Study endpoints);
however, the study was not powered to detect and exclude possible
effects and interactions, and no statistical correction was made for
multiplicity; all subgroup analyses should therefore be interpreted
as exploratory in nature. For all subgroup analyses, a nominal
interaction p value  0.05 was regarded as indicative that the
treatment effect was potentially different across subgroup
categories.
Overall ACQ-7 and AQLQ responder analyses were conducted by
Wilcoxon test to determine the percentage of patients with the
minimal clinically important difference in score of 0.5 [16,17]. Net
response rate was calculated as the difference between responseand worsening [18].
All efﬁcacy analyses were performed on the full analysis set,
deﬁned as all patients who underwent randomization and received
at least one dose of a study drug and had at least one on-treatment
efﬁcacy measurement. For longitudinal analyses, the mixed-model
repeatedmeasuresmodel accounts formissing data throughout the
course of the trial; for time-to-event analyses, patient drop-outs are
incorporated in the Cox regression analyses.3. Results
3.1. Baseline demographics
Across the two studies, 912 patients were randomized to study
treatment. Of these, 409 patients receiving tiotropium 5 mg and 405
patients receiving placebo completed the trials. Patients’ baseline
characteristics were similar across the two treatment groups
(Table 1) [9]. The majority of patients were female (60.4%), and the
mean age was 53.0 years. The mean duration of asthma was 30.3
years, most patients had never smoked (75.9%), and there were no
current smokers; ex-smokers had a mean smoking history of 5.1
pack-years.3.2. Efﬁcacy
Subgroup analyses demonstrated that, at Week 24, improve-
ments in both peak FEV1(0e3h) (Fig. 1) and trough FEV1 (Fig. S1) with
tiotropium 5 mg compared with placebo were independent of all
patient baseline characteristics assessed: gender; age; body mass
index; disease duration; age at asthma onset; smoking status; FEV1
% predicted at screening; FEV1 reversibility; LTRA use at baseline;
allergic status by clinician judgment, serum IgE, or blood eosino-
phils; B16 genotype combination; race; ethnicity; and country/re-
gion. However, the trough FEV1 improvements were of borderline
statistical signiﬁcance in the smoking status subgroup (p ¼ 0.052).
The increases in time to ﬁrst severe exacerbation (Fig. 2) and
ﬁrst episode of asthma worsening (Fig. 3) with tiotropium 5 mg
compared with placebo over the 48-week treatment period were
also not signiﬁcantly inﬂuenced by any of the patient baseline
characteristics assessed. A trend for improvement was observed in
patients with LTRA use at baseline, but did not reach statistical
signiﬁcance.
In an analysis of overall ACQ-7 responder rate data, a statistically
signiﬁcant improvement in asthma symptom control was observed
in patients treated with tiotropium 5 mg compared with placebo
after both 24 and 48 weeks (Fig. 4). At Week 24, 53.9% of patients
who received tiotropium 5 mg were responders compared with
46.9% of patients who received placebo (odds ratio [OR]: 1.32; 95%
conﬁdence interval [CI]: 1.01e1.73; p ¼ 0.04). The difference in
responder rate between tiotropium 5 mg and placebo increased at
Week 48 (OR: 1.68; 95% CI: 1.28e2.21; p < 0.001). Similar results
were observed in post hoc analyses of ﬁve-question and six-
question ACQ responder rates (see Table S2). The improvements
in ACQ-7 responder rate with tiotropium 5 mg compared with
placebo were not signiﬁcantly inﬂuenced by patients’ baseline
characteristics, except for smoking status and FEV1 % predicted at
screening at Week 24 (Fig. S2A) and blood eosinophils at Week 48
(Fig. S2B).
An analysis of AQLQ responder rate data showed numerically
greater but nonsigniﬁcant improvements with tiotropium 5 mg
versus placebo, with a numerically larger improvement also
observed at Week 48 (OR: 1.20; 95% CI: 0.92e1.57; p ¼ 0.19)
compared with Week 24 (OR: 1.12; 95% CI: 0.85e1.47; p ¼ 0.44)
(Fig. S3).
Table 1
Baseline demographics and disease characteristics.
Tiotropium 5 mg (n ¼ 456) Placebo (n ¼ 456) Total (N ¼ 912)
Gender, n (%)
Male 183 (40.1) 178 (39.0) 361 (39.6)
Female 273 (59.9) 278 (61.0) 551 (60.4)
Age (years), mean ± SD 52.2 ± 12.5 53.8 ± 12.2 53.0 ± 12.4
Body mass index (kg/m2), mean ± SD 28.2 ± 5.9 28.2 ± 6.1 28.2 ± 6.0
Race, n (%)
White 376 (82.5) 383 (84.0) 759 (83.2)
Black 22 (4.8) 25 (5.5) 47 (5.2)
Asian 56 (12.3) 47 (10.3) 103 (11.3)
Other 2 (0.4) 1 (0.2) 3 (0.3)
Smoking status, n (%)
Never smoked 340 (74.6) 352 (77.2) 692 (75.9)
Ex-smoker 116 (25.4) 104 (22.8) 220 (24.1)
Smoking history (pack-years), mean ± SD 5.4 ± 2.8 4.8 ± 2.7 5.1 ± 2.7
Concomitant treatment, n (%)a
Inhaled corticosteroids 452 (99.1) 449 (98.5) 901 (98.8)
Long-acting b2-agonists 442 (96.9) 444 (97.4) 886 (97.1)
Leukotriene receptor antagonists 96 (21.1) 107 (23.5) 203 (22.3)
Oral glucocorticoids 75 (16.4) 79 (17.3) 154 (16.9)
Theophylline 75 (16.4) 77 (16.9) 152 (16.7)
Antihistamines 79 (17.3) 55 (12.1) 134 (14.7)
Short-acting anticholinergics 34 (7.5) 33 (7.2) 67 (7.3)
Omalizumab 12 (2.6) 24 (5.3) 36 (3.9)
Long-acting anticholinergics 13 (2.9) 11 (2.4) 24 (2.6)
Age at asthma onset (years), mean ± SDb 22.6 ± 12.8 22.7 ± 13.0 22.7 ± 12.9
Duration of asthma (years), mean ± SDb 29.6 ± 13.6 31.0 ± 14.1 30.3 ± 13.9
ACQ-7 scorec, mean ± SD 2.6 ± 0.7 2.6 ± 0.7 2.6 ± 0.7
AQLQ scored, mean ± SD 4.6 ± 1.0 4.6 ± 1.1 4.6 ± 1.1
FEV1 % predicted, mean ± SDe 55.9 ± 13.1 56.0 ± 13.2 56.0 ± 13.1
FVC % predicted, mean ± SDe 79.9 ± 17.3 80.5 ± 16.8 80.2 ± 17.0
FEV1/FVC (%), mean ± SDe 58.7 ± 10.3 58.1 ± 10.0 58.4 ± 10.1
Treated set.
ACQ-7: seven-question Asthma Control Questionnaire, AQLQ: Asthma Quality of Life Questionnaire, FEV1: forced expiratory volume in 1 s, FVC: forced vital capacity, SD:
standard deviation.
a Received within 3 months before screening (Visit 1).
b Measured at screening (Visit 1).
c ACQ-7 consists of seven questions which are scored on a scale of 0 (no impairment) to 6 (maximum impairment).
d AQLQ consists of 32 questions which are scored on a scale of 1 (severely impaired) to 7 (no impairment).
e Pre-bronchodilator, measured at randomization (Visit 2).
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The subgroup analyses presented here of data from two large
phase III studies indicate that tiotropium 5 mg as add-on to ICS plus
a LABA improves lung function, reduces the risk of exacerbations
and asthma worsening, and improves asthma symptom control,
independent of a broad range of baseline characteristics in adult
patients with severe symptomatic asthma despite ICS plus LABA
therapy.
Our data show that the presence or magnitude of lung function
response, risk of exacerbations and asthma worsening following
tiotropium, when administered as add-on to ICS plus a LABA, did
not appear to be inﬂuenced by baseline characteristics, including:
gender; age; body mass index; disease duration; age at asthma
onset; smoking status; FEV1 reversibility; LTRA use at baseline; B16
genotype combination; race; ethnicity; and country/region. Re-
sponses were also shown to be independent of patients’ allergic
status by clinician judgment, serum IgE, or blood eosinophils,
which is supported by recently presented analyses of data from
these trials which did not show any interaction between risk of
exacerbations or asthma worsening over the range of IgE
(2e2000 mg/L) or blood eosinophil (0.05e7.00  109/L) levels
[19e23]. With the exception of smoking status and FEV1 % pre-
dicted at Week 24 and blood eosinophils at Week 48, improve-
ments in ACQ-7 responder rate were also found to be independent
of patients’ baseline characteristics.
Our results, however, should not be viewed as conﬁrmatory forseveral reasons. First, this is a post hoc subgroup analysis, and the
study was not powered for such analyses. Secondly, the creation of
subgroup categories increases the variation of results within sub-
groups and the likelihood of spurious signiﬁcant interactions.
Further, we made no statistical correction for multiplicity, and such
correction would have left no signiﬁcant interactions.
Nevertheless, two interactions deserve further discussion. A
numerically greater beneﬁt following the addition of once-daily
tiotropium was observed in ex-smokers across all endpoints
when compared with patients who had never smoked, with the
differences in trough FEV1 response almost reaching statistical
signiﬁcance. The reason for this observation, which applied to ex-
smokers who had not smoked for a year or more and with a
limited smoking history of only 5.1 pack-years, is unclear. The
trends for improvement in time to ﬁrst severe exacerbation and
ﬁrst episode of asthma worsening that were observed for patients
with LTRA use at baseline who were treated with tiotropium were
not observed for measures of FEV1 or ACQ-7 responder rate, and are
therefore likely to be a spurious effect.
Previous studies have suggested that responsiveness to short-
acting anticholinergics in asthma increases with age, degree of
airﬂow obstruction, and duration of disease [24e26]. Our ﬁndings
in relation to the long-acting anticholinergic tiotropium agree
broadly with those of Peters et al. [27] from the “Tiotropium Bro-
mide as an Alternative to Increased Inhaled Glucocorticoid in Pa-
tients Inadequately Controlled on a Lower Dose of Inhaled
Corticosteroid” (TALC) study of tiotropium 18 mg (via Spiriva®
Fig. 1. Peak FEV1(0e3h) at Week 24 by baseline characteristics. Full analysis set. CI: conﬁdence interval, FEV1: forced expiratory volume in 1 s, IgE: immunoglobulin E,
LTRA: leukotriene receptor antagonist, peak FEV1(0e3h): peak forced expiratory volume in 1 s within 3 h after the administration of maintenance therapy and study drug.
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asthma inadequately controlled on ICS maintenance therapy.
However, unlike in the TALC study, neither the degree of airﬂow
limitation nor the presence or absence of FEV1 reversibility in
response to a short-acting b2-agonist were found to be associatedwith a positive response in the present analysis. Our ﬁndings are
also broadly in agreement with those from the recent “Blacks and
Exacerbations on LABAvs Tiotropium” study [28] inwhich B16-Arg/
Gly polymorphisms were not associated with signiﬁcant differ-
ences in time to ﬁrst exacerbation, mean number of exacerbations,
Fig. 2. Time to ﬁrst severe asthma exacerbation over 48 weeks by baseline characteristics. Full analysis set. CI: conﬁdence interval, FEV1: forced expiratory volume in 1 s, HR: hazard
ratio, IgE: immunoglobulin E, LTRA: leukotriene receptor antagonist, NC: not calculated.
H.A.M. Kerstjens et al. / Respiratory Medicine 117 (2016) 198e206 203or lung function following tiotropium plus ICS therapy, compared
with LABA plus ICS, in black adults with asthma.
In the original publication of individual trial data from the Pri-
moTinA-asthma® trials, the mean changes in ACQ-7 and AQLQscores, compared with placebo, were modest and statistically sig-
niﬁcant at Week 24 in only one of the two trials [9]. Positive
responder rates or net treatment beneﬁt analyses provide a more
clinically useful assessment of results for analyses in which the
Fig. 3. Time to ﬁrst episode of asthma worsening over 48 weeks by baseline characteristics. Full analysis set. CI: conﬁdence interval, FEV1: forced expiratory volume in 1 s,
HR: hazard ratio, IgE: immunoglobulin E, LTRA: leukotriene receptor antagonist.
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an individual’s improvement [18,29]. In whatever way assessed, all
such comparisons are inﬂuenced by the large placebo effect seen in
these and other studies for these endpoints, presumed to relate toimproved adherence in the clinical trial environment. In the pre-
sent pooled ACQ-7 responder rate analyses, a response was deﬁned
as the minimal clinically important difference (i.e. a decrease in
ACQ-7 score from study baseline of 0.5) [16]. The addition of
Fig. 4. ACQ-7 responder rate at Weeks 24 and 48. Full analysis set. ACQ-7: seven-question Asthma Control Questionnaire, CI: conﬁdence interval, OR: odds ratio.
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tom control at Weeks 24 and 48 compared with placebo. Im-
provements in asthma symptom control with the addition of
tiotropium have also been observed in studies of patients with
moderate symptomatic asthma receiving only ICS maintenance
therapy (5 mg, OR: 1.32; 95% CI: 1.02e1.71; p ¼ 0.04; 2.5 mg, OR:
1.33; 95% CI: 1.03e1.72; p ¼ 0.03) [10]. AQLQ responder rates
(where a response was deﬁned as an increase in AQLQ score from a
study baseline of 0.5) [17] were high in both the active and pla-
cebo treatment arms. Although there was a trend toward
improvement in AQLQ responder rate over time with tiotropium
5 mg compared with placebo, this was not signiﬁcant, suggesting
that measures of asthma control and quality of life assess different
aspects of patients’ perceptions of asthma.
The beneﬁcial effects of tiotropium seen in these trials need to
be viewed within the context of the patient population studied. All
patients were symptomatic and at risk of exacerbations despite
their current treatment with ICS plus a LABA. Alternative treat-
ments at this step are limited and vary in terms of efﬁcacy, safety,
and/or availability. There is limited evidence that theophylline and
LTRAs improve asthma control or reduce exacerbations when
added to ICS plus LABA treatment [30,31], and systemic glucocor-
ticoids are associated with marked side effects [32]. Omalizumab is
indicated only for patients with speciﬁc features of allergic asthma,
and its use is further limited by cost [33]. Importantly, the safety
and tolerability of tiotropium 5 mg were found to be comparable
with those of placebo when added to ICS plus LABA maintenance
therapy [9], and the ﬁndings from our current analyses suggest that
tiotropium is effective across a broad range of patient characteris-
tics. Studies involving more detailed phenotyping across different
severities of asthma and studies including biomarkers may be
helpful in further deﬁning patients with a favorable response to
tiotropium.
In summary, the results of these subgroup analyses suggest that
once-daily tiotropium 5 mg as add-on to ICS plus a LABA may pro-
vide a beneﬁcial treatment option for patients with severe asthma
who remain symptomatic despite ICS plus a LABA, regardless of
baseline clinical features.
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